PURPOSE: To determine whether autologous (auto) or allogeneic (allo) stem-cell transplantation (SCT) improves outcome in patients with transformed follicular lymphoma compared with rituximab-containing chemotherapy alone. PATIENTS AND METHODS: This was a multicenter cohort study of patients with follicular lymphoma and subsequent biopsy-proven aggressive histology transformation. Patient, treatment, and outcome data were collected from each transplantation center and combined for analysis. A separate control group was composed of patients with transformation treated with rituximab-containing chemotherapy but not SCT. The primary end point was overall survival (OS) after transformation. RESULTS: One hundred seventy-two patients were identified: 22 (13%) treated with alloSCT, 97 (56%) with autoSCT, and 53 (31%) with rituximab-containing chemotherapy. Five-year OS after transformation was 46% for patients treated with alloSCT, 65% with autoSCT, and 61% with rituximab-containing chemotherapy (P = .24). Five-year progression-free survival (PFS) after transformation was 46% for those treated with alloSCT, 55% with autoSCT, and 40% with rituximab-containing chemotherapy (P = .12). In multivariate analysis, patients treated with autoSCT had improved OS compared with those who received rituximab-containing chemotherapy (hazard ratio [HR], 0.13; 95% CI, 0.05 to 0.34; P < .001). On the other hand, there was no OS difference between those treated with alloSCT and rituximab-containing chemotherapy (HR, 0.44; 95% CI, 0.16 to 1.24; P = .12). OS and PFS after SCT were similar between those treated with autoSCT and alloSCT. Five-year transplantation-related mortality was 23% for those treated with alloSCT and 5% for autoSCT. CONCLUSION: Patients undergoing autoSCT had better outcomes than those treated with rituximab-containing chemotherapy alone. AlloSCT did not improve outcome compared with rituximab-containing chemotherapy and was associated with clinically significant toxicity.
PURPOSE: To determine whether autologous (auto) or allogeneic (allo) stem-cell transplantation (SCT) improves outcome in patients with transformed follicular lymphoma compared with rituximab-containing chemotherapy alone. PATIENTS AND METHODS: This was a multicenter cohort study of patients with follicular lymphoma and subsequent biopsy-proven aggressive histology transformation. Patient, treatment, and outcome data were collected from each transplantation center and combined for analysis. A separate control group was composed of patients with transformation treated with rituximab-containing chemotherapy but not SCT. The primary end point was overall survival (OS) after transformation. RESULTS: One hundred seventy-two patients were identified: 22 (13%) treated with alloSCT, 97 (56%) with autoSCT, and 53 (31%) with rituximab-containing chemotherapy. Five-year OS after transformation was 46% for patients treated with alloSCT, 65% with autoSCT, and 61% with rituximab-containing chemotherapy (P = .24). Five-year progression-free survival (PFS) after transformation was 46% for those treated with alloSCT, 55% with autoSCT, and 40% with rituximab-containing chemotherapy (P = .12). In multivariate analysis, patients treated with autoSCT had improved OS compared with those who received rituximab-containing chemotherapy (hazard ratio [HR], 0.13; 95% CI, 0.05 to 0.34; P < .001). On the other hand, there was no OS difference between those treated with alloSCT and rituximab-containing chemotherapy (HR, 0.44; 95% CI, 0.16 to 1.24; P = .12). OS and PFS after SCT were similar between those treated with autoSCT and alloSCT. Five-year transplantation-related mortality was 23% for those treated with alloSCT and 5% for autoSCT. CONCLUSION:Patients undergoing autoSCT had better outcomes than those treated with rituximab-containing chemotherapy alone. AlloSCT did not improve outcome compared with rituximab-containing chemotherapy and was associated with clinically significant toxicity.
Authors: Nina D Wagner-Johnston; Brian K Link; Michelle Byrtek; Keith L Dawson; John Hainsworth; Christopher R Flowers; Jonathan W Friedberg; Nancy L Bartlett Journal: Blood Date: 2015-06-23 Impact factor: 22.113
Authors: Craig S Sauter; Matthew J Matasar; Jessica Meikle; Heiko Schoder; Gary A Ulaner; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Andrew D Zelenetz; Craig H Moskowitz Journal: Blood Date: 2015-03-10 Impact factor: 22.113
Authors: Roopesh Kansara; Joseph M Connors; Kerry J Savage; Alina S Gerrie; David W Scott; Graham W Slack; Randy D Gascoyne; Laurie H Sehn; Diego Villa Journal: Haematologica Date: 2016-06-16 Impact factor: 9.941
Authors: Frank Heinzelmann; Wolfgang Bethge; Dietrich Wilhelm Beelen; Matthias Stelljes; Peter Dreger; Marianne Engelhard; Jürgen Finke; Nikolaus Kröger; Ernst Holler; Martin Bornhäuser; Annerose Müller; Imme Haubitz; Hellmut Ottinger Journal: J Cancer Res Clin Oncol Date: 2018-04-05 Impact factor: 4.553
Authors: E Elhassadi; R Flavin; P Browne; E Conneally; P Hayden; F Quinn; E Higgins; E Vandenberghe Journal: Ir J Med Sci Date: 2017-03-21 Impact factor: 1.568
Authors: Baldeep Wirk; Timothy S Fenske; Mehdi Hamadani; Mei-Jie Zhang; Zhen-Huan Hu; Görgün Akpek; Mahmoud D Aljurf; Philippe Armand; Ernesto Ayala; Veronika Bachanova; Brian Bolwell; Mitchell S Cairo; Amanda Cashen; Yi-Bin Chen; Luciano J Costa; Shatha Farhan; César O Freytes; James L Gajewski; John Gibson; Gregory A Hale; Leona A Holmberg; Jack W Hsu; David J Inwards; Rummurti T Kamble; Dipnarine Maharaj; Richard T Maziarz; Reinhold Munker; Rajneesh Nath; Nishitha M Reddy; Craig B Reeder; David A Rizzieri; Craig S Sauter; Bipin N Savani; Harry C Schouten; Anna Sureda; Julie M Vose; Edmund K Waller; Peter H Wiernik; Robert Peter Gale; Linda J Burns; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2014-03-15 Impact factor: 5.742
Authors: Yun Soo Park; Seok Mo Lee; Ji Sun Park; Sang Kyun Bae; Hye-Kyung Shim; Won-Sik Lee; Sang-Min Lee Journal: Nucl Med Mol Imaging Date: 2017-11-21